Compare Stocks: CELC, ASND, BBIO, and EXEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$270.56 -0.2%	$257.65	$186.05 ▼ $282.15	$16.88B	0.35	675,747 shs	723,460 shs
BBIO BridgeBio Pharma	$74.84 -0.8%	$80.65	$48.78 ▼ $93.42	$14.63B	0.97	2.89 million shs	1.54 million shs
CELC Celcuity	$95.70 -0.8%	$94.66	$44.42 ▼ $151.02	$4.68B	0.19	1.08 million shs	515,514 shs
EXEL Exelixis	$59.01 -0.2%	$54.98	$33.76 ▼ $59.72	$14.62B	0.42	2.66 million shs	1.58 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+1.43%	+8.73%	+10.85%	+28.83%	+35.55%
BBIO BridgeBio Pharma	-1.42%	-4.16%	-8.12%	+11.54%	+45.47%
CELC Celcuity	+0.24%	+3.42%	+4.26%	+9.23%	+77.92%
EXEL Exelixis	+1.03%	+7.00%	+5.59%	+12.20%	+59.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$270.56 -0.2%	$257.65	$186.05 ▼ $282.15	$16.88B	0.35	675,747 shs	723,460 shs
BBIO BridgeBio Pharma	$74.84 -0.8%	$80.65	$48.78 ▼ $93.42	$14.63B	0.97	2.89 million shs	1.54 million shs
CELC Celcuity	$95.70 -0.8%	$94.66	$44.42 ▼ $151.02	$4.68B	0.19	1.08 million shs	515,514 shs
EXEL Exelixis	$59.01 -0.2%	$54.98	$33.76 ▼ $59.72	$14.62B	0.42	2.66 million shs	1.58 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+1.43%	+8.73%	+10.85%	+28.83%	+35.55%
BBIO BridgeBio Pharma	-1.42%	-4.16%	-8.12%	+11.54%	+45.47%
CELC Celcuity	+0.24%	+3.42%	+4.26%	+9.23%	+77.92%
EXEL Exelixis	+1.03%	+7.00%	+5.59%	+12.20%	+59.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.05	Buy	$310.05	14.60% Upside
BBIO BridgeBio Pharma	2.83	Moderate Buy	$101.53	35.66% Upside
CELC Celcuity	2.82	Moderate Buy	$154.55	61.49% Upside
EXEL Exelixis	2.35	Hold	$50.07	-15.16% Downside

Current Analyst Ratings Breakdown

Latest CELC, ASND, BBIO, and EXEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/2/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/1/2026	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$304.00 ➝ $312.00
9/1/2026	CELC Celcuity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/1/2026	BBIO BridgeBio Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$96.00 ➝ $110.00
9/1/2026	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$275.00 ➝ $273.00
9/1/2026	ASND Ascendis Pharma A/S	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$327.00
9/1/2026	EXEL Exelixis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/31/2026	ASND Ascendis Pharma A/S	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$333.00 ➝ $330.00
8/31/2026	ASND Ascendis Pharma A/S	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$328.00 ➝ $326.00
8/31/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$345.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$1.05B	16.12	N/A	N/A	$26.78 per share	10.10
BBIO BridgeBio Pharma	$502.08M	29.14	N/A	N/A	($12.81) per share	-5.84
CELC Celcuity	N/A	N/A	N/A	N/A	($0.26) per share	N/A
EXEL Exelixis	$2.32B	6.30	$3.05 per share	19.33	$7.44 per share	7.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	20.99	29.93	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.56	15.91	1.74	35.33%	42.17%	31.76%	11/3/2026 (Estimated)

Latest CELC, ASND, BBIO, and EXEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
BBIO BridgeBio Pharma	N/A	1.23	1.17
CELC Celcuity	6.04	8.93	8.93
EXEL Exelixis	N/A	3.46	3.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
BBIO BridgeBio Pharma	99.85%
CELC Celcuity	63.33%
EXEL Exelixis	85.27%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
BBIO BridgeBio Pharma	14.23%
CELC Celcuity	13.33%
EXEL Exelixis	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
BBIO BridgeBio Pharma	400	195.49 million	167.67 million	Optionable
CELC Celcuity	40	48.93 million	42.41 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable

CELC, ASND, BBIO, and EXEL Headlines

Recent News About These Companies

IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out

September 4 at 1:31 PM | investors.com

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

September 4 at 12:37 PM | zacks.com

What is Zacks Research's Estimate for Exelixis Q4 Earnings?

September 4 at 6:56 AM | marketbeat.com

Exelixis (NASDAQ:EXEL) Reaches New 52-Week High Following Analyst Upgrade

September 4 at 4:00 AM | americanbankingnews.com

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

September 3 at 10:41 AM | zacks.com

Exelixis (NASDAQ:EXEL) Stock Rating Upgraded by Zacks Research

September 3 at 6:05 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Exelixis, Inc. $EXEL

September 3 at 5:03 AM | marketbeat.com

Cancer stock breaks out to highs; key FDA action on watch

September 2 at 6:26 PM | msn.com

Exelixis (NASDAQ:EXEL) Sets New 12-Month High - Still a Buy?

September 2 at 10:59 AM | marketbeat.com

Exelixis, Inc. $EXEL Shares Sold by Corient Private Wealth LP

September 2 at 3:44 AM | marketbeat.com

Exelixis, Inc. (NASDAQ:EXEL) Receives $50.07 Average PT from Analysts

September 2 at 1:59 AM | americanbankingnews.com

Cancer Drug Patent Claims Upheld by CAFC

September 1 at 2:17 PM | ipwatchdog.comI

Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data

September 1 at 10:00 AM | seekingalpha.com

Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data

September 1 at 9:31 AM | seekingalpha.com

Exelixis Wins Appeal in Patent Case Against MSN Laboratories

September 1 at 4:13 AM | finance.yahoo.com

Corient Private Wealth LP Takes $4.32 Million Position in Exelixis, Inc. $EXEL

September 1 at 3:51 AM | marketbeat.com

Exelixis Secures Key Patent Victory, Extends Exclusivity

August 31, 2026 | tipranks.com

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

August 31, 2026 | businesswire.com

Jefferies Financial Group Inc. Lowers Position in Exelixis, Inc. $EXEL

August 31, 2026 | marketbeat.com

Hsbc Holdings PLC Makes New $2.59 Million Investment in Exelixis, Inc. $EXEL

August 31, 2026 | marketbeat.com

Legal & General Group Plc Invests $19.56 Million in Exelixis, Inc. $EXEL

August 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC, ASND, BBIO, and EXEL Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$270.56 -0.56 (-0.21%)

As of 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma NASDAQ:BBIO

$74.84 -0.57 (-0.76%)

As of 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Celcuity NASDAQ:CELC

$95.70 -0.73 (-0.76%)

As of 04:00 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Exelixis NASDAQ:EXEL

$59.01 -0.12 (-0.20%)

As of 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CELC, ASND, BBIO, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CELC, ASND, BBIO, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CELC, ASND, BBIO, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC, ASND, BBIO, and EXEL Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Celcuity NASDAQ:CELC

Exelixis NASDAQ:EXEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CELC, ASND, BBIO, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CELC, ASND, BBIO, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CELC, ASND, BBIO, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC, ASND, BBIO, and EXEL Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Celcuity NASDAQ:CELC

Exelixis NASDAQ:EXEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools